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PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE
ANTIHYPERTENSIVE DRUG NIFEDIPINE
Breekveldt-Postma NS, Herings RMC
PHARMO Institute, Utrecht,The Netherlands
OBJECTIVES: To assess differences in persistent use of nifedip-
ine between the different formulations of nifedipine.
METHODS: Incident nifedipine users were selected in the period
of January, 1992 to December, 2001 from the PHARMO data-
base which includes linked drug-dispensing records and hospital
records of more than 1 million subjects in deﬁned areas in The
Netherlands. Patients with unaltered formulation and dosing 
frequency of nifedipine in the ﬁrst year of follow-up with at 
least two dispensings were included in the study. Episodes of
nifedipine use were constructed for each patient. The effect of
formulation on persistence of use in the ﬁrst episode with a
maximum of one year was assessed using Cox’s proportional
hazard analyses. Other determinants of persistent use that were
taken into account were hospitalization and co-medication
before and during nifedipine use. RESULTS: A total of 7902 inci-
dent users of nifedipine were included. One year persistence for
nifedipine varied between different formulations and increased
from 18% in patients using a non-retard formulation to 33% in
patients using retard formulations up to 45% in patients using
Adalat® OROS. The median length of the ﬁrst episode was 82
days for non-retard formulations, 148 days for retard formula-
tions and 285 days for Adalat® OROS. Multivariate analyses
including gender, age, co-medication and hospitalization showed
that patients using retard formulations were 1.4 times (RR: 1.42;
95%CI: 1.20–1.67) more persistent than patients using non-
retard nifedipine. Patients using Adalat® OROS were 1.8 times
(RR: 1.84; 95%CI: 1.54–2.20) more persistent than patients
using non-retard nifedipine. A separate analysis without non-
retard formulations showed that patients using Adalat® OROS
were 1.3 times (RR: 1.34; 95%CI: 1.23–1.46) more persistent
than patients using retard formulations. CONCLUSIONS:
Patients using once daily Adalat® OROS are more persistent
with nifedipine therapy than patients using twice daily retard 
formulations of nifedipine or trice daily nifedipine.
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1Charitè Campus Virchow Klinikum, Berlin, Germany; 2Harvard
Medical School, Boston, MA, USA
OBJECTIVES: Hospital admission for CHF is an important
public health problem. Although several randomized controlled
trials (RCT) have successfully linked DMP’s to improved out-
comes and reduced readmission rates, most effects are statisti-
cally not signiﬁcant and vary regarding their magnitude. We
sought to 1) systematically combine the evidence on efﬁcacy of
disease management programs (DMP) in the treatment of con-
gestive heart failure (CHF); 2) identify reasons for the existing
heterogeneity; and 3) identify publication bias. METHODS: We
performed a systematic MEDLINE research on RCT’s investi-
gating DMP’s for CHF treatment from 1966-May, 2004. We
included all studies that were performed randomized, included
the core curriculum of a DMP (i.e., patient education, medica-
tion optimization, follow-up after discharge), and reported 
mortality and hospitalization as outcomes. We performed a meta-
analysis using random or ﬁxed effects models depending on 
the statistical heterogeneity of effects and estimated the pooled
relative risk (RR) with 95% conﬁdence intervals (95%CI). We
assessed effect heterogeneity using meta-regressions to identify
the impact of covariates on the DMP effect size. Publication bias
was assessed by inspection of funnel plots. RESULTS: Our analy-
sis included 16 studies from 5 different countries with data from
2868 patients. A random effects model which compared DMPs
vs. control groups yielded a pooled RR of 0.79 (95%CI
0.65–0.97) for mortality and of 0.87 (95%CI 0.79–0.95) for
rehospitalization during DMP. Meta-regression analysis identi-
ﬁed mean age, severity of disease (NYHA distribution), and dura-
tion of intervention as statistically signiﬁcant variables explaining
the heterogeneity. Funnel plot was asymmetric indicating a bias
towards positive studies. CONCLUSIONS: DMP’s in the CHF
treatment lead to a clinically relevant and statistically signiﬁcant
reduction of mortality and rehospitalization. Heterogeneity
across studies could largely be explained by age, severity of
disease, and duration of DMP. Our analysis may overestimate the
true DMP effect, because of a potential publication bias.
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USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS
IN THE THE NETHERLANDS
Goettsch WG1, Herings RMC2
1PHARMO Institute, Utrecht,The Netherlands; 2PHARMO Institute /
Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht,The Netherlands
OBJECTIVES: To assess the use of platelet aggregation
inhibitors in patients who were hospitalised for ischemic events
between 1998 and 2002. METHODS: Data were obtained from
the PHARMO database, which includes linked drug-dispensing
records and hospital records of more than 865,000 subjects in
deﬁned areas in The Netherlands. All patients hospitalised
between 1998 and 2002 for ischemic heart disease (IHD), cere-
brovascular disease (CVD), peripheral arterial disease (PAD) 
or having a percutaneous transluminal coronary angioplasty
(PTCA), were included in this retrospective population based
cohort study. The main outcome was the percentage of patients
using different types of platelet aggregation inhibitors speciﬁed
per indication within one month after discharge. RESULTS: In
total, 18,646 patients were included in this cohort. In 2002, 66%
of all patients with IHD, 61% of patients with CVD and 33%
of patients with PAD were treated with platelet inhibitors. More
than 80% of all patients with a ﬁrst admission for an acute
myocardial infarction or PTCA in 2002 were treated with
platelet aggregation inhibitors. Clopidogrel use (including com-
bined with aspirin) was most common in patients with IHD
(15% of all patients in 2002) and limited in patients with CVD
(5%) or PAD (2%). Clopidogrel (mainly in 2002) was almost
only combined with ASA in patients with IHD (11% of all
patients), especially in patients after PTCA (29%). CONCLU-
SIONS: There is still a considerable proportion of patients who
do not use antiplatelet therapy after ischemic events. Clopido-
grel use for secondary prevention in patients with ischemic 
vascular diseases seems to be rational given that guidelines rec-
ommend it for patients who can not be treated with aspirin.
Clopidogrel plus aspirin is mostly used in patients with IHD
treated with PTCA, suggesting that the current guidelines rec-
ommending this combination therapy in patients with acute
coronary syndrome and after PTCA, are increasingly applied.
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IN FRANCE
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